NCT07155668View on ClinicalTrials.gov

A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

PHASE3RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

November 30, 2026

Conditions
Thyroid Eye Disease
Interventions
DRUG

VRDN-003

VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).

DEVICE

Autoinjector

The autoinjector is a single-dose, disposable, ready-to-use delivery device

Trial Locations (4)

33145

RECRUITING

Hype Clinical Research, LLC, Miami

34744

RECRUITING

Ilumina Medical Research, Kissimmee

48026

RECRUITING

Fraser Eye Center, Fraser

90301

RECRUITING

United Medical Research Institute, Inglewood

All Listed Sponsors
lead

Viridian Therapeutics, Inc.

INDUSTRY